Proactive - Interviews for investors podcast

Poolbeg Pharma kicks off POLB001 Phase 2a trial with specialist partner

0:00
5:25
Rewind 15 seconds
Fast Forward 15 seconds
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF) CEO Jeremy Skillington and principal scientist Liam Tremble talked with Proactive's Stephen Gunnion about the company’s upcoming Phase 2a trial for POLB001. Tremble explained that Poolbeg has partnered with Accelerating Clinical Trials (ACT) in the UK to conduct the study, which will be led by Dr Emma Searle at the University of Manchester and the NHS Christie Foundation Trust. The Christie is one of Europe’s largest cancer centres, treating more than 60,000 patients annually, and will act as the lead site. Tremble emphasised, “We’ve been really fortunate and feel quite blessed that we found a massive amount of interest in participating on this trial.” The trial will be a single-arm, open-label Phase 2a study involving approximately 30 patients. With sufficient supply of both POLB001 and the required bispecific antibody, Poolbeg expects to generate data throughout 2026, with a focus on safety and efficacy. Skillington noted the wider potential for POLB001 in cancer immunotherapy. He said that reducing cytokine release syndrome could allow treatments to move beyond specialist centres into community hospitals. “We feel POLB001 can do that,” he added, describing the market opportunity as greater than $10 billion. He also highlighted that the company holds FDA orphan drug designation for POLB001 and has a cash runway into 2027, positioning Poolbeg to achieve multiple milestones and advance partnering discussions. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content. #PoolbegPharma #POLB001 #CancerResearch #Immunotherapy #ClinicalTrials #Biotech #Oncology #BloodCancer #PharmaNews #DrugDevelopment

More episodes from "Proactive - Interviews for investors"